8-K

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


        Date of Report (date of earliest event reported): June 1, 2004.




                                  BioTime, Inc.
             (Exact name of registrant as specified in its charter)


        California                  1-12830                      94-3127919
(State or other jurisdiction      (Commission                  (IRS Employer
     of incorporation)            File Number)               Identification No.)

                                935 Pardee Street
                           Berkeley, California 94710
                    (Address of principal executive offices)

                                 (510) 845-9535
              (Registrant's telephone number, including area code)









         Statements made in this Report that are not historical facts may
constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Such risks and uncertainties include but are not limited to those
discussed in this report and in BioTime's Annual Report on Form 10-K filed with
the Securities and Exchange Commission. Words such as "expects," "may," "will,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar
expressions identify forward-looking statements.


Item 5.  Other Events and Regulation FD Disclosure.

         Jeffrey B. Nickel Ph.D was appointed to the position of Vice President
of Business Development and Marketing effective June 1, 2004.

         Further information is incorporated by reference to Exhibit 99.1.


Item 7.  Financial Statements and Exhibits

(c) Exhibits.

Exhibit
Numbers                    Description
- -------                    -----------

99.1                       Press Release dated June 1, 2004



                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                            BIOTIME, INC.


Date:  June 3, 2004                         By:      /s/ Steven Seinberg
                                                --------------------------------
                                                         Steven Seinberg,
                                                         Chief Financial Officer








Exhibit
Numbers                    Description
- -------                    -----------

99.1                       Press Release dated June 1, 2004

EX-99.1

                                                                    EXHIBIT 99.1

  BioTime Appoints Jeffrey Nickel, Ph.D. Vice President of Business
                      Development and Marketing

    BERKELEY, Calif.--(BUSINESS WIRE)--June 1, 2004--BioTime, Inc.
(AMEX:BTX) announced the appointment of Jeffrey B. Nickel, Ph.D. to
the position of Vice President of Business Development and Marketing,
effective today. Dr. Nickel has served on the Board of Directors since
1997. His more than three decades of service to the chemical,
pharmaceutical, and biotechnology industries has resulted in the
successful international marketing of various cardiovascular drugs,
vaccines, anti-inflammatories, dermatologicals, neurologicals and
other products.
    As president of his own biopharmaceutical and healthcare
consulting company Nickel & Associates, Dr. Nickel has been
instrumental in a number of significant licensing agreements and
acquisitions. He has played important roles in assisting many emerging
biotech companies with collaborative and commercial development,
marketing, business and strategic planning, and raising capital.
Several client accounts include business development consulting for
Armour Pharmaceutical Co./Rhone-Poulenc Rorer, Inc., Genelabs
Technologies, Inc., SangStat Medical Corporation, PPD Pharmaco,
ProtoGene Laboratories and others. His company has been involved in
agreements pertaining to cell therapy, gene therapy, infectious
disease, blood products and drug delivery for companies such as Inhale
Therapeutic Systems, Inc., Medarex, Inc. and Applied Immune Sciences,
Inc.
    Prior to starting his consulting business in 1991, Dr. Nickel
spent three years in international marketing for Syntex Corporation.
His earlier background includes 15 years in research, sales and
marketing for Merck & Company. Dr. Nickel received his Ph.D. (1970)
and M.S. (1967) in Organic Chemistry from Rutgers University. He
conducted his undergraduate studies in Organic Chemistry at The
College of William and Mary (B.S., 1965).
    "We are very fortunate to have Jeff Nickel join the Company on a
full time basis," said Dr. Hal Sternberg, Vice President of Research
and member of the Office of the President at BioTime. "His wealth of
knowledge and broad expertise in business development and
pharmaceutical product marketing will be invaluable as we optimize the
opportunities before us."
    Judith Segall, Vice President of Operations and member of the
Office of the President, added, "Jeff has an enormous number of
contacts in the biotech, pharmaceutical and financial industries and
will play a vital role in expanding both our business and product
development activities."

    About BioTime, Inc.

    BioTime, headquartered in Berkeley, California develops blood
plasma volume expanders, blood replacement solutions for hypothermic
(low temperature) surgery, organ preservation solutions and technology
for use in surgery, emergency trauma treatment and other applications.
BioTime's lead product Hextend(R) is manufactured and distributed in
the U.S. and Canada by Abbott Laboratories' global hospital products
spin-off Hospira, Inc. under an exclusive licensing agreement.
Information about BioTime can be found on the web at
www.biotimeinc.com.

    Forward Looking Statements

    The matters discussed in this press release include
forward-looking statements which are subject to various risks,
uncertainties and other factors that could cause actual results to
differ materially from the results anticipated. Such risks and
uncertainties include but are not limited to the results of clinical
trials of BioTime products; the ability of BioTime and its licensees
to obtain additional FDA and foreign regulatory approval to market
BioTime products; competition from products manufactured and sold or
being developed by other companies; and the price of and demand for
BioTime products. Other risk factors are discussed in BioTime's Annual
Report on Form 10-K filed with the Securities and Exchange Commission.

    Financial Relations Board serves as financial relations counsel to
this company, is acting on the company's behalf in issuing this
bulletin and receiving compensation therefor. The information
contained herein is furnished for information purposes only and is not
to be construed as an offer to buy or sell securities.

    CONTACT: BioTime, Inc.
             Judith Segall, 510-845-9535
             or
             Financial Relations Board
             Kristen McNally, 310-407-6548 (Investor/Analyst)
             kmcnally@financialrelationsboard.com